Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
PRQR Quote, Financials, Valuation and Earnings
Last price:
$2.13
Seasonality move
:
13.33%
Day range:
$1.96 - $2.15
52-week range:
$1.07 - $3.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.16x
P/B ratio:
3.16x
Volume:
659.1K
Avg. volume:
397K
1-year change:
-38.9%
Market cap:
$211.7M
Revenue:
$20.4M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $978.59 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -5.57% | -135.86% | $97.00 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 10.75% | -67.59% | $31.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.78 | -- | -3.65% | $41.87 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 14.37% | -38.51% | $58.48 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$2.01 | $8.88 | $211.7M | -- | $0.00 | 0% | 12.16x |
|
ARGX
argenx SE
|
$915.97 | $978.59 | $56.4B | 46.56x | $0.00 | 0% | 19.54x |
|
MRUS
Merus NV
|
$96.12 | $97.00 | $7.3B | -- | $0.00 | 0% | 120.82x |
|
PHAR
Pharming Group NV
|
$15.81 | $31.00 | $1.1B | 1,105.59x | $0.00 | 0% | 2.98x |
|
PHVS
Pharvaris NV
|
$29.37 | $41.87 | $1.9B | -- | $0.00 | 0% | -- |
|
QURE
uniQure NV
|
$25.48 | $58.48 | $1.6B | -- | $0.00 | 0% | 87.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PHVS
Pharvaris NV
|
0.19% | 0.173 | 0.04% | 12.56x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
ProQR Therapeutics NV vs. Competitors
-
Which has Higher Returns PRQR or ARGX?
argenx SE has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 25.88%. ProQR Therapeutics NV's return on equity of -67.34% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PRQR or ARGX?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 341.54%. On the other hand argenx SE has an analysts' consensus of $978.59 which suggests that it could grow by 6.84%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 ARGXargenx SE16 1 0 -
Is PRQR or ARGX More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock PRQR or ARGX?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or ARGX?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than argenx SE quarterly revenues of $948M. ProQR Therapeutics NV's net income of -$12.9M is lower than argenx SE's net income of $245.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 46.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 12.16x versus 19.54x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M ARGXargenx SE19.54x 46.56x $948M $245.4M
-
Which has Higher Returns PRQR or MRUS?
Merus NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -786.17%. ProQR Therapeutics NV's return on equity of -67.34% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About PRQR or MRUS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 341.54%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.92%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 MRUSMerus NV2 14 0 -
Is PRQR or MRUS More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock PRQR or MRUS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or MRUS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than Merus NV quarterly revenues of $12.2M. ProQR Therapeutics NV's net income of -$12.9M is higher than Merus NV's net income of -$95.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 12.16x versus 120.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M MRUSMerus NV120.82x -- $12.2M -$95.5M
-
Which has Higher Returns PRQR or PHAR?
Pharming Group NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 7.71%. ProQR Therapeutics NV's return on equity of -67.34% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About PRQR or PHAR?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 341.54%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 96.08%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group NV, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHARPharming Group NV2 0 0 -
Is PRQR or PHAR More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or PHAR?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHAR?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than Pharming Group NV quarterly revenues of $96.9M. ProQR Therapeutics NV's net income of -$12.9M is lower than Pharming Group NV's net income of $7.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,105.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 12.16x versus 2.98x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M PHARPharming Group NV2.98x 1,105.59x $96.9M $7.5M
-
Which has Higher Returns PRQR or PHVS?
Pharvaris NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of --. ProQR Therapeutics NV's return on equity of -67.34% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About PRQR or PHVS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 341.54%. On the other hand Pharvaris NV has an analysts' consensus of $41.87 which suggests that it could grow by 37.14%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHVSPharvaris NV8 1 0 -
Is PRQR or PHVS More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or PHVS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHVS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are larger than Pharvaris NV quarterly revenues of --. ProQR Therapeutics NV's net income of -$12.9M is higher than Pharvaris NV's net income of -$43.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 12.16x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns PRQR or QURE?
uniQure NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -2175.87%. ProQR Therapeutics NV's return on equity of -67.34% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PRQR or QURE?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 341.54%. On the other hand uniQure NV has an analysts' consensus of $58.48 which suggests that it could grow by 129.5%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 QUREuniQure NV9 2 0 -
Is PRQR or QURE More Risky?
ProQR Therapeutics NV has a beta of 0.176, which suggesting that the stock is 82.397% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock PRQR or QURE?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or QURE?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than uniQure NV quarterly revenues of $3.7M. ProQR Therapeutics NV's net income of -$12.9M is higher than uniQure NV's net income of -$80.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 12.16x versus 87.06x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV12.16x -- $3.4M -$12.9M QUREuniQure NV87.06x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
